Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by StrikingMooseon Mar 20, 2018 9:43am

134 Views

Post# 27745416

RE:Level 2 PLZ? What will be the SP we can reach today??

Level 2 Quote

Level two quotes - Bid
Number of Shares		Bid Price
14,500 shares	14,500	0.670
33,000 shares	33,000	0.660
182,500 shares	182,500	0.650
45,000 shares	45,000	0.640
39,500 shares	39,500	0.630
55,000 shares	55,000	0.620
74,500 shares	74,500	0.610
276,000 shares	276,000	0.600
42,500 shares	42,500	0.590
63,000 shares	63,000	0.580

Level two quotes - Ask
Ask Price	Number of Shares
0.680	4,500	4,500 shares
0.690	44,500	44,500 shares
0.700	253,500	253,500 shares
0.710	14,500	14,500 shares
0.720	116,500	116,500 shares
0.730	14,500	14,500 shares
0.740	18,500	18,500 shares
0.750	227,000	227,000 shares
0.760	15,000	15,000 shares
0.770	8,000